Xeris Biopharma Holdings (XERS) Non-Current Deferred Tax Liability (2020 - 2024)

Xeris Biopharma Holdings' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $3.3 million for Q2 2024.

• Quarterly Non-Current Deferred Tax Liability rose 16.92% year-over-year to $3.3 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $3.3 million (up 16.92% YoY) and the FY2023 annual result came in at $2.3 million, down 35.53% from the prior year.
• Non-Current Deferred Tax Liability was $3.3 million for Q2 2024 at Xeris Biopharma Holdings, up from $2.6 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $5.3 million in Q4 2021 and bottomed at $442000.0 in Q4 2020.
• A 5-year average of $3.2 million and a median of $3.4 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability soared 1100.45% — and 2023, when it plunged 35.53%.
• Xeris Biopharma Holdings' Non-Current Deferred Tax Liability stood at $442000.0 in 2020, then surged by 1100.45% to $5.3 million in 2021, then sank by 33.7% to $3.5 million in 2022, then sank by 35.53% to $2.3 million in 2023, then surged by 46.56% to $3.3 million in 2024.
• Business Quant data shows XERS's Non-Current Deferred Tax Liability at $3.3 million in Q2 2024, $2.6 million in Q1 2024, and $2.3 million in Q4 2023.